Opioid dependence and pregnancy: minimizing stress on the fetal brain

American Journal of Obstetrics and Gynecology

Volumn 216, Issue 3, 2017, Pages 226-231

  McCarthy, John J ^a   Leamon, Martin H ^a   Finnegan, Loretta P ^b   Fassbender, Catherine ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Executive Officer of the College on Problems of Drug Dependence and Finnegan Consulting   (United States)

Author keywords

buprenorphine; fetal stress programming; methadone; neonatal abstinence syndrome; opioid dependence; pharmacokinetics; pregnancy

Indexed keywords

BUPRENORPHINE; METHADONE;

ANALGESIA; FEMALE; FETUS BRAIN; HUMAN; MATERNAL STRESS; MEDICAL EDUCATION; MENTAL STRESS; METHADONE TREATMENT; NEONATAL ABSTINENCE SYNDROME; NEWBORN; OPIATE ADDICTION; PHYSICIAN; PREGNANCY; PRIORITY JOURNAL; REVIEW; ROOMING IN; BRAIN DISEASES; COMPLICATION; FETAL DISEASES; OPIOID-RELATED DISORDERS; PREGNANCY COMPLICATIONS;

BRAIN DISEASES; BUPRENORPHINE; FEMALE; FETAL DISEASES; HUMANS; METHADONE; OPIOID-RELATED DISORDERS; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 85019841060     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2016.10.003     Document Type: Review

References (49)

1. 1 US Government Accountability Office. Prenatal drug use and newborn health: federal efforts need better planning and coordination. Available at: gao.gov/products/GAO-15-203. Accessed December 2, 2016.
2. 2 Maeda, A., Bateman, B.T., Clancy, C.R., Creanga, A.A., Leffert, L.R., Opioid abuse and dependence during pregnancy: temporal trends and obstetrical outcomes. Anesthesiology 121 (2014), 1158–1165.
3. 3 Whiteman, V.E., Salemi, J.L., Mogos, M.F., Cain, M.A., Alyiu, M.H., Salihu, H.M., Maternal opioid use during pregnancy and its impact on perinatal morbidity, mortality, and the cost of medical care in the United States. J Pregnancy, 2014, 2014, 906723.
4. 4 Patrick, S.W., Schumacher, R.E., Benneyworth, B.D., Krans, E.E., McAllister, J.M., Davis, M.M., Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. JAMA 307 (2012), 1934–1940.
5. 5 McCarthy, J.J., Leamon, M.H., Willits, N.H., Salo, R., The effects of methadone dose regimen on neonatal abstinence syndrome. J Addict Med 9 (2015), 105–110.
6. 6 Rewire News. Tennessee Fetal Assault Law (SB 1391). Available at: http://data.rhrealitycheck.org/law/tennessee-pregnancy-criminalization-law-sb-1391/. Accessed October 26, 2016.
7. 7 McCarthy, J.J., Terplan, M., Detoxification from opiates during pregnancy: stressing the fetal brain. Am J Obstet Gynecol 215 (2016), 670.e1–670.e2.
8. 8 Kaltenbach, K., Finnegan, L.P., Developmental outcomes of children born to methadone maintained women: a review of longitudinal studies. Neurobehav Toxicol Teratol 6 (1984), 271–275.
9. 9 ACOG Committee on Health Care for Underserved Women; American Society of Addiction Medicine. Opioid abuse, dependence, and addiction in pregnancy. Committee opinion no. 524. Obstet Gynecol 119 (2012), 1070–1076.
10. 10 McCarthy, J., Intrauterine abstinence syndrome (IAS) during buprenorphine inductions and methadone tapers: can we assure the safety of the fetus?. J Matern Fetal Neonatal Med 25 (2012), 109–112.
11. 11 Macedo, T.R., Relvas, J., Fontes Ribeiro, C.A., et al. Plasma catecholamines during an ultrarapid heroin detoxification. Ann N Y Acad Sci 914 (2000), 303–310.
12. 12 Stevenson, D.K., Sunshine, P., Benitz, W.E., Fetal and neonatal brain injury. 3rd ed., 2005, Cambridge University Press, Cambridge, UK, 287.
13. 13 Zuspan, F.P., Gumpel, J.A., Mejia-Zelaya, A., Madden, J., Davis, R., Fetal stress from methadone withdrawal. Am J Obstet Gynecol 122 (1975), 43–46.
14. 14 Dashe, J.S., Jackson, G.L., Olsher, D.A., Zane, E.H., Wendel, G.D., Opiate detoxification in pregnancy. Obstet Gynecol 92 (1998), 854–858.
15. 15 Terplan, M., The obstetrical and neonatal impact of maternal opioid detoxification in pregnancy. Am J Obstet Gynecol 210 (2014), 375–376.
16. 16 Maymon, E.L., Chaim, W., Furman, B., Ghezzi, F., Shoham Vardi, I., Meconium stained amniotic fluid in very low risk pregnancies at term gestation. Eur J Obstet Gynecol Reprod Biol 80 (1998), 169–173.
17. 17 Bell, J., Towers, C.V., Hennessy, M.D., Heitzman, C., Smith, B., Chattin, K., Detoxification from opiate drugs during pregnancy. Am J Obstet Gynecol 215 (2016), 374.e1–374.e6.
18. 18 Kapoor, A., Dunn, E., Kostaki, A., Andrews, M.H., Matthews, S.G., Fetal programming of hypothalamo-pituitary-adrenal function: prenatal stress and glucocorticoids. J Physiol 572 (2006), 31–44.
19. 19 Mulder, E.J., Robles de Medina, P.G., Huizink, A.C., Van den Bergh, B.R., Buitelaar, J.K., Visser, G.H., Prenatal maternal stress: effects on pregnancy and the (unborn) child. Early Hum Dev 70 (2002), 3–14.
20. 20 Zhang, G.F., Ren, Y.P., Sheng, L.X., et al. Dysfunction of the hypothalamic-pituitary-adrenal axis in opioid dependent subjects: effects of acute and protracted abstinence. Am J Drug Alcohol Abuse 34 (2008), 760–768.
21. 21 Gowland, R.L., Entangled lives: implications of the developmental origins of health and disease hypothesis for bioarchaeology and the life course. Am J Phys Anthropol 158 (2015), 530–540.
22. 22 Nijhuis, J.G., Fetal behavior. Neurobiol Aging 24:Suppl (2003), S41–S47.
23. 23 Tolia, V.N., Patrick, S.W., Bennett, M.M., et al. Increasing incidence of the neonatal abstinence syndrome in US neonatal ICUs. N Engl J Med 372 (2015), 2118–2126.
24. 24 Sharpe, C., Kuschel, C., Outcomes of infants born to mothers receiving methadone for pain management in pregnancy. Arch Dis Child Fetal Neonatal Ed 89 (2004), 33–36.
25. 25 Bogen, D.L., Perel, J.M., Helsel, J.C., et al. Pharmacologic evidence to support clinical decision making for peripartum methadone treatment. Psychopharmacology 225 (2013), 441–451.
26. 26 Center for Substance Abuse Treatment. Medication-assisted treatment for opioid addiction in opioid treatment programs. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2005. (Treatment Improvement Protocol [TIP] Series, no. 43.) Chapter 13. Medication-assisted treatment for opioid addiction during pregnancy. Available at: http://www.ncbi.nlm.nih.gov/books/NBK64148/. Accessed December 2, 2016.
27. 27 Whittmann, B.K., Segal, S., A comparison of the effects of single- and split-dose methadone administration on the fetus: an ultrasound evaluation. Int J Addict 26 (1991), 213–218.
28. 28 Jansson, L.J., DiPietro, J.A., Velez, M., et al. Maternal methadone dosing schedule and fetal neurobehavior. J Matern Fetal Neonatal Med 22 (2009), 29–35.
29. 29 Hulse, G.K., Milne, E., English, D.R., Holman, D.J., The relationship between maternal use of heroin and methadone and infant birth weight. Addiction 92 (1997), 1571–1579.
30. 30 Johnson, K., Grenough, A., Gerada, A.C., Maternal drug use and length of neonatal unit stay. Addiction 98 (2003), 785–789.
31. 31 Cleary, B.J., Donnelly, J., Strawbridge, J., et al. Methadone dose and neonatal abstinence syndrome-systematic review and meta-analysis. Addiction 105 (2010), 2071–2084.
32. 32 Jones, H.E., Jansson, L.M., O'Grady, K.E., Kaltenbach, K., The relationship between maternal methadone dose at delivery and neonatal outcome: methodological and design considerations. Neurotoxicol Teratol 39 (2013), 110–115.
33. 33 Bier, J.B., Finger, A.S., Bier, B.A., Johnson, T.A., Growth and developmental outcome of infants with in-utero exposure to methadone vs buprenorphine. J Perinatol 35 (2015), 656–659.
34. 34 Jones, H.E., Kaltenbach, K., Heil, S.H., et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 363 (2010), 2320–2331.
35. 35 Meyer, M.C., Johnston, A.M., Crocker, A.M., Heil, S.H., Methadone and buprenorphine for opioid dependence during pregnancy: a retrospective cohort study. J Addict Med 9 (2015), 81–86.
36. 36 Brown, S.M., Holtzman, M., Kim, T., Kharasch, E.D., Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active. Anesthesiology 115 (2011), 1251–1260.
37. 37 Kacinko, S.L., Jones, H.E., Johnson, R.E., Choo, R.E., Concheiro-Guisan, M., Huestis, M.A., Urinary excretion of buprenorphine, norbuprenorphine, buprenorphine-glucuronide, and norbuprenorphine-glucuronide in pregnant women receiving buprenorphine treatment. Clin Chem 55 (2009), 1177–1187.
38. 38 Raffa, R.B., Ding, Z., Examination of the preclinical antinociceptive efficacy of buprenorphine and its designation as a full or partial agonist. J Ac Pain 9 (2007), 145–152.
39. 39 Hosseini, S.M., Biglan, M.W., Larkby, C., Brooks, M.M., Gorin, M.B., Day, N.L., Trait anxiety in pregnant women predicts offspring birth outcomes. Paediatr Perinat Epidemiol 23 (2009), 557–566.
40. 40 Cottrell, E.C., Seckl, J.R., Prenatal stress, glucocorticoids and the programming of adult disease. Front Behav Neurosci, 3, 2009, 19.
41. 41 Patrick, S.W., Kaplan, H.C., Passarella, M., Davis, M.M., Lorch, S.A., Variations in treatment of neonatal abstinence syndrome in US children's hospitals, 2004-2011. J Perinatol 34 (2014), 867–872.
42. 42 Morgan, B.E., Horn, A.R., Bergman, N.J., Should neonates sleep alone. Biol Psych 70 (2011), 817–825.
43. 43 Holmes, A.V., Atwood, E.C., Whalen, B., et al. Rooming-in to treat neonatal abstinence syndrome: improved family-centered care at lower cost. Pediatrics 137 (2016), e1–e9.
44. 44 Saiki, T., Lee, S., Hannam, S., Grenough, A., Neonatal abstinence syndrome–postnatal ward versus neonatal unit management. Eur J Pediatr 169 (2010), 95–98.
45. 45 Baewert, A., Jagsch, R., Winklbaur, B., et al. Influence of site differences between urban and rural American and Central European opioid-dependent women and neonatal outcome characteristics. Eur Addict Res 18 (2012), 130–139.
46. 46 Finnegan, L.P., Kron, R.E., Connaughton, J.F., Emich, J.P., A scoring system for evaluation and treatment of the neonatal abstinence syndrome: a clinical and research tool. Morselli, P.L., Garattini, S., Sereni, F., (eds.) Basic and therapeutic aspects of perinatal pharmacology, 1975, Raven Press, New York, 139–153.
47. 47 D'Apolito K, Finnegan L. Assessing signs and symptoms of neonatal abstinence using the Finnegan scoring tool, an interobserver reliability program. Available at: http://www.neoadvances.com. Accessed December 2, 2016.
48. 48 Finnegan L. Substance abuse in Canada: licit and illicit drug use during pregnancy. Maternal, neonatal and early childhood consequences. Ottawa, Ontario. Canadian Center on Substance Abuse. Available at: http://www.ccsa.ca/Resource%20Library//CCSA-Drug-Use-during-Pregnancy-Report-2013-en.pdf. Accessed December 2, 2016.
49. 49 Weiner, S.M., Finnegan, L.P., Drug withdrawal in the neonate. Carter, B., Gardner, S., (eds.) Handbook of neonatal intensive care, 8th ed., 2015, Mosby-Year Book Inc, St. Louis, MO.